½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting

  • »¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

    021-54845833/15800441009

    Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

    µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > ÆäËû¿¹Ìå > AADAC ¿¹Ô­£¨ÖØ×éµ°°×£©

    ²úÆ·ÖÐÐÄ

    ×îвúÆ·

    • AADAC ¿¹Ô­£¨ÖØ×éµ°°×£©

      ¹æ¸ñ£º
      ¼Û¸ñ£º£¤
      • Æ·ÅÆ : ͨεÉúÎï
      • Ŀ¼ºÅ : TW15659
      • Ó¦Óà : ½ö¹©¿ÆÑÐʹÓÃ
      • »õÆÚ : ÏÖ»õ
      • ¹æ¸ñ £º100ug
    • ÉÌÆ·ÏêÇé
    • ²Î¿¼ÎÄÏ×
    • ˵Ã÷ÊéÏÂÔØ
    • ÉÌÆ·ÆÀÂÛ0
    • Ïà¹Ø²úÆ·

    ÖÐÎÄÃû³Æ£ºAADAC ¿¹Ô­£¨ÖØ×éµ°°×£©

    Ó¢ÎÄÃû³Æ£º AADAC Antigen (Recombinant Protein)

    ±ð      Ãû£º Arylacetamide deacetylase; DAC; CES5A1

    ´¢      ´æ£º Àä¶³£¨-20¡æ£©

    Ïà¹ØÀà±ð£º ¿¹Ô­

    ¸Å  Êö£º

    Fusion protein corresponding to C terminal 250 amino acids of human AADAC


    ¼¼Êõ¹æ¸ñ£º


    Full name:

    Arylacetamide deacetylase

    Synonyms:

    DAC; CES5A1

    Swissprot:

    P22760

    Gene Accession:

    BC032309

    Purity:

    >85%, as determined by Coomassie blue stained SDS-PAGE

    Expression system:

    Escherichia coli

    Tags:

    His tag C-Terminus, GST tag N-Terminus

    Background:

    Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens. Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide, which is an antiandrogen drug used for the treatment of prostate cancer that occasionally causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.


    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿